These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 9679561

  • 1. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
    Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC.
    Chem Biol Interact; 1998 Apr 24; 111-112():277-305. PubMed ID: 9679561
    [Abstract] [Full Text] [Related]

  • 2. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
    Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC.
    Pigment Cell Res; 1997 Aug 24; 10(4):236-49. PubMed ID: 9263331
    [Abstract] [Full Text] [Related]

  • 3. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells.
    Benathan M, Alvero-Jackson H, Mooy AM, Scaletta C, Frenk E.
    Melanoma Res; 1992 Dec 24; 2(5-6):305-14. PubMed ID: 1337997
    [Abstract] [Full Text] [Related]

  • 4. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
    Ongaro A, Pellati A, De Mattei M, De Terlizzi F, Rossi CR, Campana LG.
    Anticancer Drugs; 2015 Mar 24; 26(3):284-92. PubMed ID: 25514113
    [Abstract] [Full Text] [Related]

  • 5. Markedly decreased expression of glutathione S-transferase pi gene in human cancer cell lines resistant to buthionine sulfoximine, an inhibitor of cellular glutathione synthesis.
    Yokomizo A, Kohno K, Wada M, Ono M, Morrow CS, Cowan KH, Kuwano M.
    J Biol Chem; 1995 Aug 18; 270(33):19451-7. PubMed ID: 7642628
    [Abstract] [Full Text] [Related]

  • 6. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
    Prezioso JA, FitzGerald GB, Wick MM.
    J Invest Dermatol; 1992 Sep 18; 99(3):289-93. PubMed ID: 1512464
    [Abstract] [Full Text] [Related]

  • 7. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
    Wu XX, Ogawa O, Kakehi Y.
    Int J Oncol; 2004 Jun 01; 24(6):1489-97. PubMed ID: 15138592
    [Abstract] [Full Text] [Related]

  • 9. L-S,R-buthionine sulfoximine: historical development and clinical issues.
    Bailey HH.
    Chem Biol Interact; 1998 Apr 24; 111-112():239-54. PubMed ID: 9679558
    [Abstract] [Full Text] [Related]

  • 10. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
    Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR.
    Br J Cancer; 1991 Aug 24; 64(2):215-20. PubMed ID: 1892748
    [Abstract] [Full Text] [Related]

  • 11. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
    Ali-Osman F, Antoun G, Wang H, Rajagopal S, Gagucas E.
    Mol Pharmacol; 1996 Jun 24; 49(6):1012-20. PubMed ID: 8649339
    [Abstract] [Full Text] [Related]

  • 12. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
    Chen G, Waxman DJ.
    Biochem Pharmacol; 1994 Mar 15; 47(6):1079-87. PubMed ID: 8147907
    [Abstract] [Full Text] [Related]

  • 13. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
    Kable EP, Favier D, Parsons PG.
    Cancer Res; 1989 May 01; 49(9):2327-31. PubMed ID: 2706620
    [Abstract] [Full Text] [Related]

  • 14. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
    Xu BH, Gupta V, Singh SV.
    Arch Biochem Biophys; 1994 Jan 01; 308(1):164-70. PubMed ID: 8311448
    [Abstract] [Full Text] [Related]

  • 15. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP, Reynolds CP.
    Bone Marrow Transplant; 2002 Aug 01; 30(3):135-40. PubMed ID: 12189530
    [Abstract] [Full Text] [Related]

  • 16. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
    Soble MJ, Dorr RT.
    Anticancer Res; 1988 Aug 01; 8(1):17-22. PubMed ID: 3358633
    [Abstract] [Full Text] [Related]

  • 17. Schisandrin B-induced increase in cellular glutathione level and protection against oxidant injury are mediated by the enhancement of glutathione synthesis and regeneration in AML12 and H9c2 cells.
    Chiu PY, Ko KM.
    Biofactors; 2006 Aug 01; 26(4):221-30. PubMed ID: 17119269
    [Abstract] [Full Text] [Related]

  • 18. Buthionine sulfoximine diverts the melanogenesis pathway toward the production of more soluble and degradable pigments.
    Galván I, Wakamatsu K, Alonso-Alvarez C, Solano F.
    Bioorg Med Chem Lett; 2014 May 01; 24(9):2150-4. PubMed ID: 24703231
    [Abstract] [Full Text] [Related]

  • 19. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P, Loh SY, Kelland LR, Harrap KR.
    Int J Cancer; 1993 Nov 11; 55(5):848-56. PubMed ID: 8244583
    [Abstract] [Full Text] [Related]

  • 20. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF.
    J Clin Oncol; 1996 Jan 11; 14(1):249-56. PubMed ID: 8558205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.